Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804161 | 0.79 | NPC1 (0.48) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL1926867 | 0.77 | RAB9A (0.47) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL12800745 | 0.77 | P2RX3 (0.39) | — | |
| SCHEMBL14804190 | 0.74 | MAPT (0.51) | NPC1RAB9AHPGDALDH1A1GAA | |
| SCHEMBL30140451 | 0.74 | NPC1 (0.43) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL3048656 | 0.74 | NPC1 (0.43) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL13125277 | 0.73 | NPC1 (0.56) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL13125236 | 0.71 | RAB9A (0.54) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL10188109 | 0.70 | DRD4 (0.46) | NPC1RAB9ACASP3SENP7HPGD | |
| SCHEMBL12180345 | 0.70 | RAB9A (0.62) | NPC1RAB9AHPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | NPC1 2554/4885RAB9A 2257/4885CASP3 771/4885 |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | NPC1 2554/4885RAB9A 2257/4885CASP3 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.